Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1,10-phenanthroline
-
weak
1-Mercapto-9,11,15-trihydroxyprosta-5,13-diene
-
inhibition of prostaglandin G1 synthesis
1-Mercapto-9-oxo-11,15-dihydroxyprosta-5,13-dione
-
inhibition of prostaglandin G1 synthesis
12-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
14-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
15-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase and peroxidase activity PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
2,3-Dimercaptopropanol
-
inhibition of prostaglandin G1 synthesis
2-hydroxybutyric acid
-
weak
3,6-bis(3-[[(furan-2-yl)methyl]amino]propyl)-9H-xanthen-9-one
-
3,6-bis(5-[[(furan-2-yl)methyl]amino]pentyl)-9H-xanthen-9-one
-
3,6-bis[3-(2-methyl-1H-indol-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(4-methylpiperazin-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(4-nitroanilino)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(cyclohexylamino)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(morpholin-4-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-(piperidin-1-yl)propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(1H-pyrazol-3-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(2-chloropyridin-3-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(4H-1,2,4-triazol-4-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(pyrazin-2-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[3-[(pyridin-2-yl)amino]propyl]-9H-xanthen-9-one
-
3,6-bis[4-(1H-imidazol-2-yl)butyl]-9H-xanthen-9-one
-
3,6-bis[5-(2-methyl-1H-indol-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(4-methylpiperazin-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(4-nitroanilino)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(cyclohexylamino)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(morpholin-4-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-(piperidin-1-yl)pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(1H-pyrazol-3-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(2-chloropyridin-3-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(4H-1,2,4-triazol-4-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(piperidin-1-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(pyrazin-2-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[5-[(pyridin-2-yl)amino]pentyl]-9H-xanthen-9-one
-
3,6-bis[6-(1H-imidazol-2-yl)hexyl]-9H-xanthen-9-one
-
5,8,11,14-Eicosatetraynoic acid
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
6-methoxy-2-naphthyl acetic acid
-
active metabolite of nabumetone, isozyme 1, 50% inhibition at 0.2-0.8 mM, isozyme 2, 50% inhibition at 0.015-0.55 mM
6-methylnaphthylacetic acid
-
recombinant protein, 50% inhibition at 0.08-0.1 mM
6-[2,4-difluorophenoxy]-5-methyl-sulfonylamino-1-indanone
-
CGP28238, an isozyme-2 specific inhibitor, 65% inhibition at 100 nM
9,11-Dihydroxy-15S-mercaptoprosta-5,13-dienoic acid
-
or 15R-isomer, inhibition of prostaglandin G1 synthesis
9-nitroarachidonic acid
nitro-fatty acid inhibition is due to a slow, tightly binding mechanism, it inhibits oxygenase activity and peroxidase activity of PGHS-1, kinetics, overview. Inactivation of PGHS by nitroarachidonic acid involves two sequential steps: an initial reversible binding event, followed by a practically irreversible event leading to an inactivated enzyme. Inactivation is associated with irreversible disruption of heme binding to the protein, the inhibitor induces heme release from Fe2+-protoporphyrin-PGHS-1. In activated human platelets, nitroarachidonic acid significantly decreases PGHS-1-dependent thromboxane B2 formation in parallel with a decrease in platelet aggregation
anirolac
-
isozyme 1, 50% inhibition at 0.0007 mM, isozyme 2, 50% inhibition at 0.009 mM
bicarbonate
-
bicarbonate enhances peroxynitrite-mediated peroxidase inactivation
BW 755C
-
recombinant protein, 50% inhibition at 0.01-0.02 mM
DCM-extract of Angelicae dahuricae radix
0.1% inhibition of PGHS-1; 38.8% inhibition of PGHS-2
-
DCM-extract of Angelicae sinsesis radix
55.8% inhibition of PGHS-2; 75.0% inhibition of PGHS-1
-
DCM-extract of Atractylodis lanceae rhizoma
46.9% inhibition of PGHS-1; 50.3% inhibition of PGHS-2
-
DCM-extract of Atractylodis macrocephalae rhizoma
47.0% inhibition of PGHS-2; 58.6% inhibition of PGHS-1
-
DCM-extract of Cinnamomi ramulus
48.4% inhibition of PGHS-2; 73.5% inhibition of PGHS-1
-
DCM-extract of Houttuyniae herba
40.9% inhibition of PGHS-2; 46.8% inhibition of PGHS-1
-
DCM-extract of Notopterygii rhizoma seu radix
-2.1% inhibition of PGHS-2; 42.6% inhibition of PGHS-1
-
DCM-extract of Piperis sarmentosi herba
10.1% inhibition of PGHS-2; 47.2% inhibition of PGHS-1
-
DCM-extract of Platycodi radix
70.1% inhibition of PGHS-2; 77.8% inhibition of PGHS-1
-
DCM-extract of Zanthoxyli pericarpium
18.3% inhibition of PGHS-1; 31.3% inhibition of PGHS-2
-
DCM-extract of Zingiberis rhizoma
41.3% inhibition of PGHS-2; 52.9% inhibition of PGHS-1
-
delta-tocopherol-13'-carboxychromanol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
-
delta-tocotrienol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
delta-tocotrienol-13'-carboxychromanol
-
inhibits isoform Cox-1 and suppresses Cox-1 mediated formation of thromboxane in collagen-stimulated rat's platelets
-
diethyldithiocarbamate
-
-
dihydrolipoic acid
-
inhibition of prostaglandin G1 synthesis
dithiothreitol
-
inhibition of prostaglandin G1 synthesis
docosahexaenoic acid
-
isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.015 mM
Eicosa-5,8,11,14-tetraynoic acid
-
-
ellagic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
etodalac
-
recombinant protein, 50% inhibition at 0.06-0.07 mM
ETYA
-
recombinant protein, 50% inhibition at 0.015-0.025 mM
fatty acid
-
of low molecular mass
fenclofenac
-
isozyme 1, 50% inhibition at 0.007 mM, isozyme 2, 50% inhibition at 0.004 mM
flosulide
-
selective for isozyme 2, 50% inhibition at 130 nM
Flufenamic acid
-
50% inhibition at 0.02 mM
L-745
-
isozyme 1, 50% inhibition at 0.369 mM, isozyme 2, 50% inhibition at 0.002 mM
Mefenamic acid
-
isozyme 1, 50% inhibition at 0.01 mM, isozyme 2, 50% inhibition at 0.0003 mM
meloxicam
-
isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.0004 mM
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
n-hexane extract of Angelicae dahuricae radix
42.4% inhibition of PGHS-2; 52.5% inhibition of PGHS-1
-
n-hexane extract of Angelicae sinsesis radix
61.5% inhibition of PGHS-2; 73.0% inhibition of PGHS-1
-
n-hexane extract of Atractylodis lanceae rhizoma
67.4% inhibition of PGHS-1; 68.3% inhibition of PGHS-2
-
n-hexane extract of Atractylodis macrocephalae rhizoma
46.1% inhibition of PGHS-1; 48.9% inhibition of PGHS-2
-
n-hexane extract of Cinnamomi ramulus
23.6% inhibition of PGHS-2; 46.6% inhibition of PGHS-1
-
n-hexane extract of Houttuyniae herba
43.4% inhibition of PGHS-2; 50.3% inhibition of PGHS-1
-
n-hexane extract of Notopterygii rhizoma seu radix
64.9% inhibition of PGHS-2; 69.6% inhibition of PGHS-1
-
n-hexane extract of Piperis sarmentosi herba
52.4% inhibition of PGHS-1; 65.0% inhibition of PGHS-2
-
n-hexane extract of Platycodi radix
48.7% inhibition of PGHS-1; 55.1% inhibition of PGHS-2
-
n-hexane extract of Zanthoxyli pericarpium
24.9% inhibition of PGHS-2; 48.5% inhibition of PGHS-1
-
n-hexane extract of Zingiberis rhizoma
77.5% inhibition of PGHS-2; 83.4% inhibition of PGHS-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
niflumic acid
-
isozyme 1, 50% inhibition at 0.016 mM, isozyme 2, 50% inhibition at 0.0001 mM
Non-steroidal anti-inflammatory agents
-
O2
-
the cyclooxygenase reaction is inhibited by an excess of dissolved oxygen, 0.5 mM O2 causes twofold decrease in the initial rate and maximal yield
PD-98059
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
SB203580
inhibitor of p38, reduces the PGHS-2 response to oxygen and glucose depivation by approximately 50%
SC58125
-
isozyme 1, 50% inhibition at 0.039 mM, isozyme 2, 50% inhibition at 0.0003 mM
sulindac sulfide
-
isozyme 1, 50% inhibition at 0.0004 mM, isozyme 2, 50% inhibition at 0.012 mM
suprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.002mM
Tannic acid
-
at high concentration and in presence of cofactors inhibition, at low concentrations stimulation
U0126
MEK inhibitor, blocks specifically the activation of ERK1/2 and the PGHS-2 mRNA response to oxygen and glucose depivation, hence ERK is a mediator of PGHS-2 gene expression
5,8,11,14-Eicosatetraynoic acid
-
-
5,8,11,14-Eicosatetraynoic acid
complete inhibition at 0.04 mM
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 7.6fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-2-hydroxy-N-(propan-2-yl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 7.6fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-cyclohexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-amino-N-hexyl-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 44fold selectivity for isoform Cox-2 over Cox-1
-
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
-
DuP-697, selective for isozyme 2
5-bromo-2-[4-fluorophenyl]-3-[4-methylsulfonylphenyl]-thiophene
-
50% inhibition at 8.7 nM
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 29.7fold selectivity for isoform Cox-2 over Cox-1
-
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-N-(4-methylphenyl)benzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 29.7fold selectivity for isoform Cox-2 over Cox-1
-
Acetylsalicylic acid
-
inhibition of prostaglandin G1 synthesis
Acetylsalicylic acid
-
an irreversible inhibitor of both hPHS-1 and hPHS-2
Acetylsalicylic acid
-
isozyme 1, complete inhibition, isozyme 2, change in reaction, main product from arachidonate is 15-hydroxyeicosatetraenoic acid
Acetylsalicylic acid
-
irreversible inhibitor
Acetylsalicylic acid
-
inhibition of oxygenase activity by acetylating a serine residue of the enzyme
albumin
-
-
-
albumin
-
bovine serum albumin inhibits by binding of arachidonic acid
-
aspirin
-
-
aspirin
-
cyclooxygenase activity
diclofenac
-
recombinant protein, 50% inhibition at 0.04 mM
diclofenac
-
50% inhibition at 9.4 nM
diclofenac
-
isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0015 mM
diclofenac
-
isozyme 1, 50% inhibition at 0.0003 mM, isozyme 2, 50% inhibition at 18 nM
DUP-697
-
a standard PHS-2 inhibitor
DUP-697
-
a PHS-2-specific inhibitor
flurbiprofen
-
isozyme 1, 50% inhibition at 40 nM, isozyme 2, 50% inhibition at 500 nM
flurbiprofen
-
isozyme 1, 50% inhibition at 0.0009 mM, isozyme 2, 50% inhibition at 0.0009 mM
flurbiprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.003 mM
flurbiprofen
-
cyclooxygenase inhibitor
Ibuprofen
-
recombinant protein, 50% inhibition at 0.04 mM
Ibuprofen
-
50% inhibition at 0.253 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.0026 mM, isozyme 2, 50% inhibition at 0.0015 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.018 mM
Ibuprofen
-
isozyme 1, 50% inhibition at 0.09 mM, isozyme 2, 50% inhibition at 0.008 mM
indomethacin
-
inhibition of prostaglandin G1 synthesis
indomethacin
-
acts on isozyme 1 and 2, 85% inhibition at 100 nM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
reversible and time-dependent inhibition
indomethacin
-
50% inhibition at 100 nM
indomethacin
-
isozyme 1, 50% inhibition at 0.0017 mM, isozyme 2, 50% inhibition at 0.025 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
isozyme 1 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0003 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
isozyme 1, 50% inhibition at 0.005 mM, isozyme 2, 50% inhibition at 0.130-0.160 mM
indomethacin
-
inhibition in gastrointestinal tissues
indomethacin
-
inhibition in gastrointestinal tissues
Ketoprofen
-
isozyme 1, 50% inhibition at 0.0005 mM, isozyme 2, 50% inhibition at 0.0025 mM
Ketoprofen
-
isozyme 1, 50% inhibition at 0.011 mM, isozyme 2, 50% inhibition at 0.018 mM
Meclofenamic acid
-
isozyme 1, 50% inhibition at 0.002 mM, isozyme 2, 50% inhibition at 0.015 mM
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 135fold selectivity for isoform Cox-2 over Cox-1
-
N-butyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 135fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 120fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[(E)-[(2,5-dihydroxyphenyl)methylidene]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 120fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 114fold selectivity for isoform Cox-2 over Cox-1
-
N-cyclohexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 114fold selectivity for isoform Cox-2 over Cox-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 145fold selectivity for isoform Cox-2 over Cox-1
-
N-hexyl-5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxybenzamide
-
5-aminosalicylic acid derivative, additionally inhibits lipoxygenase Lox-5. 145fold selectivity for isoform Cox-2 over Cox-1
-
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
NS-398, selective for isozyme 2
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
50% inhibition at 81 nM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
isozyme 1, 50% inhibition at 0.017 mM, isozyme 2, 50% inhibition at 0.0001 mM
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide
-
little inhibition in gastrointestinal tissues
naproxen
-
recombinant protein, 50% inhibition at 0.05-0.06 mM
naproxen
-
isozyme 1, 50% inhibition at 0.0006 mM, isozyme 2, 50% inhibition at 0.002 mM
naproxen
inhibitor of cyclooxigenase reaction; inhibitor of cyclooxigenase reaction
nimesulide
-
isozyme 1, 50% inhibition at 0.07 mM, isozyme 2, 50% inhibition at 0.0013 mM
nimesulide
-
isozyme 1, 50% inhibition at 0.009 mM, isozyme 2, 50% inhibition at 0.0005 mM
nimesulide
-
inhibits the cyclooxygenase activity, a COX-2-specific inhibitor
Non-steroidal anti-inflammatory agents
-
inhibition of cyclooxygenase activity
-
Non-steroidal anti-inflammatory agents
-
inhibition of cyclooxygenase activity
-
NS-398
inhibits PTGS2
piroxicam
-
isozyme 1, 50% inhibition at 0.009-0.024 mM, isozyme 2, 50% inhibition at 0.070-0.240 mM
piroxicam
-
isozyme 1, 50% inhibition at 0.075 mM, isozyme 2, 50% inhibition at 0.002 mM
quercetin
-
quercetin 3-O-glucoside
-
quercetin 3-O-glucoside
-
SC-560
-
a standard PHS-1 inhibitor
SC-560
-
a PHS-1-specific inhibitor
additional information
algal PGHS is not inhibited by non-steroidal anti-inflammatory drugs that inhibit the mammalian enzymes
-
additional information
-
algal PGHS is not inhibited by non-steroidal anti-inflammatory drugs that inhibit the mammalian enzymes
-
additional information
-
effect of cofactor, enzyme and substrate concentration on inhibition by human serum, haptoglobin and albumin
-
additional information
-
mechanism of selective inhibition
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
-
guava leaf extract inhibits the catalytic activity of the PGHS-1 isoform using linoleic acid as substrate (IC50 value of 0.055 mg of dry leaf extract); guava leaf extract inhibits the catalytic activity of the PGHS-2 isoform using linoleic acid as substrate (IC50 value of 0.56 mg of dry leaf extract); isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
-
no inhibition of PGHS-2 oxygenase activity by 9-nitro-, 12-nitro-, 14-nitro, and 15-nitroarachidonic acid and by nitrooleic acid and nitrolinoleic acid; other nitro fatty acids tested, such as nitrooleic acid and nitrolinoleic acid, are unable to inhibit the enzyme activity
-
additional information
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
-
nimesulide inhibits PGHS-2 turnover in most brain regions
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-
additional information
guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; guava leaf extract inhibits the catalytic activity of the PGHS-1 and PGHS-2 isoforms using linoleic acid as substrate; isozyme PGHS-1 is hardly inhibited by ellagic acid; isozyme PGHS-2 is hardly inhibited by ellagic acid
-